VP, Gout Core Asset Team; CAT Lead

VP
- Gout Core Asset Team (CAT) Lead

The VP
- Gout Core Asset Team (CAT) Lead is a senior cross‑functional executive accountable for defining and executing the global strategy for Sobi’s Gout portfolio (two pre‑launch assets). The role focuses on lifecycle management (LCM), regulatory and commercial readiness, and long‑term value maximization with the U.S. as the primary market. This position reports to the Vice President, Head of U.S. Immunology and Global Gout Franchise.

• Define and lead the global asset strategy for the Gout portfolio, aligned with corporate priorities.
• Develop and maintain a high‑quality Integrated Project Plan (IPP), including resourcing and budget.
• Drive lifecycle management (LCM) to extend product value and optimize portfolio performance.
• Contribute to portfolio‑level prioritization and resource allocation across Sobi’s immunology pipeline.
• Ensure readiness and execution of U.S. regulatory submissions and approvals.
• Align evidence generation plans with asset strategy, guiding clinical, medical, and real‑world data priorities.
• Assess ex‑U.S. markets to identify viable pathways and develop focused geographic launch plans.
• Engage and build relationships, in coordination with Medical, with select top‑KOLs to inform the strategy.

• Lead and develop the Core Asset Team (CAT), integrating expertise from R&D, Medical Affairs, Tech Ops, Commercial, and Project Management.
• Partner closely with regional and functional leaders to ensure alignment between global strategy and local execution.
• Ensure effective coordination between CAT members and their respective functional asset teams to drive execution of functional plans.
• Collaborate closely with executive leadership and cross‑functional teams across R&D, Medical Affairs, Market Access, Regulatory, Tech Ops, and Commercial to ensure strategic alignment and execution.
• Collaborate with Alliance Management to ensure effective partnerships and joint governance.

• Build the investment cases and ensure budgets within approved guardrails.
• Coordinate and oversee CAT members’ strategy execution, leveraging functional expertise.
• Prepare for and represent the asset in ExCom Portfolio Reviews and other key decision forums.
• Lead proactive scenario and mitigation planning to manage strategic, regulatory, and commercial risks impacting asset value.
• Identify risks and implement corrective actions early, escalating to governance committees as needed.
• Maintain a single source of truth for asset data and performance metrics.

• Partner with U.S. and regional teams to ensure launch readiness, assess ex‑U.S. market potential, and maintain consistent launch excellence where applicable.
• Collaborate with Insights & Analytics to inform strategy and pre‑launch planning.
• Translate market insights into actionable strategies for differentiation and growth.
• Foster a culture of accountability, collaboration, and scientific excellence.

• Master’s degree in a relevant field (science background strongly preferred).
• 10+ years in global biopharma leadership, ideally in immunology, rheumatology, or metabolic diseases.
• Proven track record in lifecycle management, global asset strategy, and launch leadership.
• Strong cross‑functional leadership and stakeholder management skills.
• Strategic thinker with disciplined execution and sound business judgment.
• Skilled communicator and influencer across senior levels.
• Culturally agile, with experience in U.S., Europe (in particular Scandinavian and Swiss), and other international business environments.
• Fluent in English; additional languages a plus.

• Competitive 401(k) match to support your financial future.
• Tuition and wellness reimbursements to invest in your personal and professional growth.
• Comprehensive medical, dental, and vision package to prioritize your health and well‑being.
• Additional recognition awards to celebrate your achievements.
• Base salary is $275,000–$340,000 annually, with short‑term and long‑term bonuses as outlined in the plan details.

Sobi is an Equal Opportunity…